ArticleLeukemia2022
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis.
Abstract read
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 56 citations in OpenAlex.
- Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.Leukemia · 2024Trial
- Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.Leukemia · 2022Trial
- Langerhans cell histiocytosis: molecular mechanisms underlying pathogenesis and emerging targeted therapeutics.Cancer metastasis reviews · 2026Review
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- Clinical characteristics, genomic profiling, treatments, and outcomes of Langerhans cell sarcoma.Orphanet journal of rare diseases · 2026Article
- Case Report: Erdheim-Chester disease with liver involvement successfully treated with trametinib.Frontiers in oncology · 2026Article
- Orbital Langerhans Cell Histiocytosis in Young Pediatric Patients: Two Case Reports and Literature Review.Pediatric health, medicine and therapeutics · 2026Article
- Langerhans Cell Histiocytosis WithEJHaem · 2025Article
- [Chinese expert consensus on the diagnosis and treatment of adult Langerhans cell histiocytosis (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- [A case of adult temporal bone langerhans cell histiocytosis presenting as posterior canal dehiscence syndrome and literature review].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Review
- Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations.Molecular biotechnology · 2025Review
- High resolution chest computed tomography responses for a cohort of adult with pulmonary Langerhans cell histiocytosis.Annals of hematology · 2025Article
- Revisiting the molecular landscape of Rosai-Dorfman disease: insights from whole exome sequencing of Saudi patients.Frontiers in oncology · 2025Article
- Case report: Primary subcutaneous Rosai-Dorfman-Destombes of the scalp with intra-cranial involvement: diagnosis and treatment of a rare case with literature review.Frontiers in neurology · 2025Article
- Clinical Spectrum and Outcome of Kidney Involvement in Non-Langerhans Histiocytosis.Kidney international reports · 2025Article
- BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature.Journal of hematopathology · 2024Review
- Article
- Circulating Tumor DNA Combining with Imaging Analysis for Lesion Detection of Langerhans Cell Histiocytosis in Children.Children (Basel, Switzerland) · 2024Article
- Manifestations and outcomes of digestive tract involvement in adult Langerhans cell histiocytosis.Annals of hematology · 2024Article
- Liver involvement with Langerhans cell histiocytosis in adults.The oncologist · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Jia Chen *Department of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.ORCID http://orcid.org/0000-0003-3486-7705
Ai-Lin Zhao *Department of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Ming-Hui DuanDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.ORCID http://orcid.org/0000-0003-2130-6300
Hao CaiDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.ORCID http://orcid.org/0000-0003-2153-9470
Xue-Min GaoDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.ORCID http://orcid.org/0000-0001-8032-060X
Ting LiuDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Jian SunDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Zhi-Yong LiangDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Dao-Bin ZhouDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.ORCID http://orcid.org/0000-0002-1592-1932
Xin-Xin CaoDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. caoxinxin@pumch.cn.ORCID http://orcid.org/0000-0001-7884-3073
Jian LiDepartment of Hematology, Peking Union Medical Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. lijian@pumch.cn.ORCID http://orcid.org/0000-0002-4549-0694
Chinese Academy of Medical Sciences & Peking Union Medical College · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdultAgedBiomarkers, TumorCase-Control StudiesFemaleFollow-Up StudiesHistiocytosisHumansMaleMAP Kinase Kinase 1Middle AgedMyeloid CellsPrognosisProto-Oncogene Proteins B-rafRetrospective StudiesBiomarkers, TumorBRAF protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Proto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.